Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

CaptBeer Dec. 28 at 4:04 PM

$AMRN https://www.linkedin.com/feed/update/urn:li:ugcPost:7410645988832612352?commentUrn=urn%3Ali%3Acomment%3A%28ugcPost%3A7410645988832612352%2C7411071864514736128%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287411071864514736128%2Curn%3Ali%3AugcPost%3A7410645988832612352%29

0 · Reply

SmartOptionsAlert Dec. 28 at 11:25 AM

🔎 $AMRN Options Scan Update (05:25 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

DoMoreCharity Dec. 28 at 4:01 AM

$AMRN https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3618671#.XtqhCv2KLeU.twitter

1 · Reply

smartinvest101 Dec. 28 at 3:59 AM

$AMRN I have sports injury induced arthritis on my right knee. I asked this group almost a year back on whether folks have experienced positive effect on arthritis pain while taking vascepa because of its anti inflammatory property. Few people shared extremely positively experience. I tried getting vascepa in USA but could never get a prescription from my orthopedic surgeon. Now I am visiting India and decided to try vascepa (of course it’s generic from DR Reddy). I can just buy it from drug store in India. No prescription needed. I have been taking 4 grams of IPE daily for two weeks now and can say the arthritis pain is almost gone. This is gold standard. I can personally attest. I hope someday the real value of the drug is exposed to the entire world.

1 · Reply

mikesterz7 Dec. 27 at 11:39 PM

$AMRN Get it now

1 · Reply

bearcreekzeke Dec. 27 at 11:08 PM

$AMRN My investment in this company is an enigma. Incredible life-saving drug with proven efficacy in reducing the risk of heart attacks and strokes by reducing inflammation and reversing the narrowing of arteries, with seemingly limitless potential, but with no one to champion the drug, it is withering on the vine. What a tragedy!

1 · Reply

HamarinU2 Dec. 27 at 10:54 PM

$AMRN AMRN #5 Trending on Stocktwits Top trending ticker WHY AMRN IS TRENDING Amarin is currently trending due to several near-term legal decisions, including a Supreme Court conference on its infringement case and critical antitrust rulings, alongside the FDA's recent clarification that fenofibrates offer no cardiovascular benefit, which opens a significant market opportunity for Vascepa. The community is actively debating China's NRDL exclusion as a strategic price-preserving move, while speculation around a potential acquisition, particularly involving Novartis, continues to drive much conversation.

0 · Reply

MoneyGroupLLC Dec. 27 at 10:34 PM

Enter: $AMRN Calls Strike Price: $15 Expiry Date: JAN 16 2026 Buy in Price: $0.34 - $0.50 Sell Price: $0.51 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Md80dog Dec. 27 at 10:23 PM

$AMRN market cap $3.4 billion

0 · Reply

Md80dog Dec. 27 at 10:21 PM

$AMRN is it HIK??

0 · Reply

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 7 weeks ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 2 months ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 3 months ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 4 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 4 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 4 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 5 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 5 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 5 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 6 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 8 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 8 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 8 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 9 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 9 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 9 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 10 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 10 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 10 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 10 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 11 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 2 years ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

CaptBeer Dec. 28 at 4:04 PM

0 · Reply

SmartOptionsAlert Dec. 28 at 11:25 AM

🔎 $AMRN Options Scan Update (05:25 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

DoMoreCharity Dec. 28 at 4:01 AM

$AMRN https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3618671#.XtqhCv2KLeU.twitter

1 · Reply

smartinvest101 Dec. 28 at 3:59 AM

1 · Reply

mikesterz7 Dec. 27 at 11:39 PM

$AMRN Get it now

1 · Reply

bearcreekzeke Dec. 27 at 11:08 PM

1 · Reply

HamarinU2 Dec. 27 at 10:54 PM

0 · Reply

MoneyGroupLLC Dec. 27 at 10:34 PM

0 · Reply

Md80dog Dec. 27 at 10:23 PM

$AMRN market cap $3.4 billion

0 · Reply

Md80dog Dec. 27 at 10:21 PM

$AMRN is it HIK??

0 · Reply

Md80dog Dec. 27 at 10:09 PM

$AMRN

0 · Reply

Md80dog Dec. 27 at 10:07 PM

$AMRN HKMPY $4.6 Billion market cap

0 · Reply

Md80dog Dec. 27 at 9:55 PM

$AMRN anyone know what symbol Hikma trades under? Is it worth thinking about shorting it?

0 · Reply

HamarinU2 Dec. 27 at 3:45 PM

$AMRN got to agree with you Declan👇IMO the ST board has deteriorated the past year+ Nothing newsworthy posted and pumpers like SBR, afraid of his own shadow, block dissent and create their individual echo chambers. A few new Richards a month claim to have bought at $3 and sold in the $20’s pre split. Must be an epic experience to travel back in time and share the journey to all of us

0 · Reply

Dtilac Dec. 27 at 11:48 AM

$AMRN 🙏https://x.com/thehealthb0t/status/2004746401331515704?s=20

0 · Reply

bennfine Dec. 26 at 10:30 PM

$AMRN was that 50k shares after hours?? Am I reading that right on nasdaq.com?

1 · Reply

declanaidan Dec. 26 at 10:03 PM

$AMRN Gotta say iHub is now de facto source for Amarn due diligence. It is incredible what a few over there have researched and uncovered, expecially now on the legal front, which looks very promising, very soon.

1 · Reply

Flounderguykk Dec. 26 at 9:30 PM

$AMRN any long time long's know how to get brokers to build options for Jan2027? I would like to buy a few, TIA

0 · Reply

bennfine Dec. 26 at 9:12 PM

$AMRN anyone know anything??

1 · Reply

CEVIN Dec. 26 at 8:43 PM

$AMRN Guess no Christmas rally again this year but at least we have scrapped ourselves off multi- year low…really hope 2026 is the first year since 2019 we don’t sink any lower .

0 · Reply

Finitemaf Dec. 26 at 6:35 PM

$AMRN let’s get this litigation resolved in 26 and get this dog sold! Good luck longs!

0 · Reply

ians Dec. 26 at 5:16 PM

$AMRN Imagine Wegovy + Vascepa combo pill.🤔 Reduce weight by 14% & Reduce CVD risk by >25%. In one ORAL pill form. Now That's potent. 🤑☘️💎 What is NVO waiting for? That would be the next step in Wegovy's product lifecycle. And would present a challenge to LLY's Orforglipron slated to be approved in '26 https://stocktwits.com/ians/message/637287107 https://finance.yahoo.com/news/fda-approves-novo-nordisks-wegovy-230300802.html

0 · Reply

Market Cap	294.01M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	104,700
Avg Vol	110,372
Day's Range	N/A - N/A
Shares Out	20.79M
Stochastic %K	64%
Beta	0.71
Analysts	Hold
Price Target	$12.00